生命科学资讯

Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess

After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate

GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug

After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst

Werewolf weighs sale or merger as cash reserves whimper

Evinova reels in AI clinical development deals with Astellas and AstraZeneca

FDA freezes enrollment in MacroGenics cancer trial after patient death

Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal

GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech

Labcorp, PathAI expand partnership to offer AI tech for digital pathology diagnostics

Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study

Allurion stock balloons as FDA signs off on its weight loss gastric system

Medtronic's diabetes business MiniMed eyes $784M IPO

Organon pays $27.5M upfront to license Sebela's hormone-free copper IUD

Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking

Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months

‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

FDA issues safety alert on Trividia blood glucose monitors